Berendsen H H, Broekkamp C L
Department of CNS Pharmacology, Organon International B.V., Oss, The Netherlands.
Eur J Pharmacol. 1991 Mar 5;194(2-3):201-8. doi: 10.1016/0014-2999(91)90106-z.
The pharmacological characteristics of hindlimb scratching induced by serotonergic compounds were studied. We conclude that hindlimb scratching induced by serotonergic compounds is mediated by a serotonin1D (5-HT1D) or 5-HT1D-like receptor outside the blood-brain barrier because hindlimb scratching could be induced by s.c. injection of 5-methoxytryptamine (5-MeOT), 5-carboxamidotryptamine (5-CT), bufotenine, 5-hydroxytryptamine (5-HT) and tryptamine. These compounds have high affinity for 5-HT1A and 5-HT1D receptors. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), the 5-HT1C receptor agonist MK 212, and the mixed 5-HT1C/5-HT2 receptor agonists (dl)-1-(2,5 dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and quipazine did not induce hindlimb scratching. Rather, the latter compounds attenuated 5-MeOT-induced hindlimb scratching. The 5-HT releasing compounds fenfluramine and p-chloroamphetamine (PCA) inhibited whereas the 5-HT re-uptake inhibitors fluvoxamine and indalpine potentiated 5-MeOT-induced hindlimb scratching. 5-MeOT-induced hindlimb scratching could be inhibited dose dependently by the alpha 2-adrenoceptor blockers yohimbine and rauwolsince, which also have high affinity for 5-HT1D receptors, whereas the alpha 2-adrenoceptor blocker piperoxan only weakly counteracted hindlimb scratching. Haloperidol, apomorphine, morphine, clonidine and methiothepin strongly attenuated hindlimb scratching, atropine, naloxone and ICS 205930 attenuated it weakly whereas domperidone, methylatropine and mepyramine were inactive in doses up to 10 mg/kg. Hindlimb scratching induced by 5-MeOT was potentiated by the 5-HT receptor antagonists metergoline, methysergide, mesulergine, mianserin, ritanserin and xylamidine. Hindlimb scratching was not induced by i.c.v. injection of 5-MeOT.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了血清素能化合物诱导的后肢搔抓的药理学特性。我们得出结论,血清素能化合物诱导的后肢搔抓是由血脑屏障外的血清素1D(5-HT1D)或5-HT1D样受体介导的,因为皮下注射5-甲氧基色胺(5-MeOT)、5-羧酰胺色胺(5-CT)、蟾蜍色胺、5-羟色胺(5-HT)和色胺可诱导后肢搔抓。这些化合物对5-HT1A和5-HT1D受体具有高亲和力。5-HT1A受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)、5-HT1C受体激动剂MK 212以及5-HT1C/5-HT2受体混合激动剂(dl)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)和喹哌嗪未诱导后肢搔抓。相反,后一种化合物减弱了5-MeOT诱导的后肢搔抓。5-HT释放化合物芬氟拉明和对氯苯丙胺(PCA)具有抑制作用,而5-HT再摄取抑制剂氟伏沙明和茚达品增强了5-MeOT诱导的后肢搔抓。5-MeOT诱导的后肢搔抓可被α2-肾上腺素能受体阻滞剂育亨宾和萝芙木碱剂量依赖性抑制,它们对5-HT1D受体也具有高亲和力,而α2-肾上腺素能受体阻滞剂哌罗克生仅微弱地对抗后肢搔抓。氟哌啶醇、阿扑吗啡、吗啡、可乐定和美噻吨强烈减弱后肢搔抓,阿托品、纳洛酮和ICS 205930微弱减弱后肢搔抓,而多潘立酮、甲基阿托品和吡拉明在高达10mg/kg的剂量下无活性。5-HT受体拮抗剂麦角林、甲基麦角新碱、美舒麦角、米安色林、利坦色林和赛拉米定增强了5-MeOT诱导的后肢搔抓。脑室内注射5-MeOT未诱导后肢搔抓。(摘要截短于250字)